The efficacy of ibrutinib in the treatment of Richter syndrome.
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Mazie
M
Tsang
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Tait D
TD
Shanafelt
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Timothy G
TG
Call
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Wei
W
Ding
Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
Asher
A
Chanan-Khan
Department of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ.
Jose F
JF
Leis
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Grzegorz S
GS
Nowakowski
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Deborah
D
Bowen
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Michael
M
Conte
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Susan M
SM
Schwager
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Susan L
SL
Slager
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Neil E
NE
Kay
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Curtis A
CA
Hanson
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Sameer A
SA
Parikh
D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010880:Piperidines; D011241:Prednisone / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D000069283:Rituximab; D013577:Syndrome; D014750:Vincristine / Q000627:therapeutic use
D058846:Antibodies, Monoclonal, Murine-Derived; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C571759:R-CHOP protocol; C551803:ibrutinib; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine; D011241:Prednisone